Cost-Utility Analysis of Disease-Modifying Drugs in Relapsing-Remitting Multiple Sclerosis in Iran

Value in Health ◽

10.1016/j.jval.2013.08.1833 ◽

2013 ◽

Vol 16 (7) ◽

pp. A624

Author(s):

A. Imani ◽

M. Golestani ◽

J.S. Tabrizi ◽

A. Janati

Keyword(s):

Multiple Sclerosis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Disease Modifying Drugs ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

Value in Health ◽

10.1016/s1098-3015(11)70789-6 ◽

2000 ◽

Vol 3 (5) ◽

pp. 362-363

Author(s):

E Orlewska ◽

P Mierzejewski ◽

A Czlonkowska

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Utility Analysis Of Dimethyl Fumarate Versus Fingolimod And Teriflunomide In Patients With Relapsing-Remitting Multiple Sclerosis In Colombia

Value in Health ◽

10.1016/j.jval.2016.09.506 ◽

2016 ◽

Vol 19 (7) ◽

pp. A434 ◽

Author(s):

J Ordóñez ◽

P Serafini ◽

M Machado

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PNP15: COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)64043-0 ◽

2003 ◽

Vol 6 (3) ◽

pp. 277

Author(s):

C Rubio-Terrés ◽

F Medina ◽

I Aristegui ◽

G Izquierdo

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND45 Cost-Utility Analysis of Teriflunomide in Naïve VS. Previously Treated Patients with Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health ◽

10.1016/j.jval.2020.08.1370 ◽

2020 ◽

Vol 23 ◽

pp. S631

Author(s):

C. Lazzaro ◽

R. Bergamaschi ◽

M. Zaffaroni ◽

R. Totaro ◽

D. Paolicelli

Keyword(s):

Multiple Sclerosis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Previously Treated Patients ◽

Previously Treated ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Utility Analysis of Intramuscular Interferon Beta-1b Versus Subcutaneous Interferon Beta-1b and Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in Colombia

Value in Health ◽

10.1016/j.jval.2016.03.204 ◽

2016 ◽

Vol 19 (3) ◽

pp. A63 ◽

Author(s):

J Ordoñez ◽

A Delgado

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Utility Analysis of Delayed-Release Dimethyl Fumerate For The Treatment of Relapsing-Remitting Multiple Sclerosis In Portugal

Value in Health ◽

10.1016/j.jval.2015.09.2471 ◽

2015 ◽

Vol 18 (7) ◽

pp. A758 ◽

Author(s):

L Silva Miguel ◽

J de Sá ◽

B Pinheiro ◽

C Acosta

Keyword(s):

Multiple Sclerosis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria

Journal of Medical Economics ◽

10.1080/13696998.2018.1556668 ◽

2018 ◽

Vol 22 (3) ◽

pp. 226-237 ◽

Author(s):

Evelyn Walter ◽

Thomas Berger ◽

Barbara Bajer-Kornek ◽

Florian Deisenhammer

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Natalizumab Treatment ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Utility Analysis Of Alemtuzumab Versus Natalizumab For The Treatment Of Relapsing-Remitting Multiple Sclerosis: Us Payer Perspective

Value in Health ◽

10.1016/j.jval.2016.09.490 ◽

2016 ◽

Vol 19 (7) ◽

pp. A431 ◽

Author(s):

A Smith ◽

L Hashemi ◽

I Ma

Keyword(s):

Multiple Sclerosis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Payer Perspective ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND35 Belgian Cost-Utility Analysis of Gilenya® (Fingolimod) in the Management of Adults with Active Relapsing Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2011.08.501 ◽

2011 ◽

Vol 14 (7) ◽

pp. A323

Author(s):

S. Drieskens ◽

K. Moeremans

Keyword(s):

Multiple Sclerosis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Value in Health ◽

10.1016/j.jval.2014.08.906 ◽

2014 ◽

Vol 17 (7) ◽

pp. A399 ◽

Author(s):

E. Soini ◽

C. Asseburg ◽

M.L. Sumelahti

Keyword(s):

Multiple Sclerosis ◽

Supportive Care ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text